TreatSMA exclusive webinar with respiratory expert Dr John Bach

A couple of weeks ago we had the honour of hosting Dr John Bach for an exclusive webinar looking at how to manage the respiratory system of SMA sufferers.

The webinar was absolutely amazing, a few technical problems here and there, but overall the content was 2.5 hours of brilliant advice that you would struggle to get elsewhere. Dr Bach is a leader in his field with a number of books and hundreds of papers published, so it really is an honour to have him as a friend of TreatSMA. The session focused on non-invasive ventilation, and contained case studies and information of patients that Dr Bach for many years.

Dr. John R. Bach received his medical degree from the College of Medicine and Dentistry of New Jersey in 1976, and completed his residency training in Physical Medicine and Rehabilitation at New York University in 1980.

He is a fellow of the Association of Academic Physiatrists, the American College of Chest Physicians, and a fellow of the American Academy of Physical Medicine and Rehabilitation.

Dr. Bach was the Clinical Supervisor of the Howard Rusk Ventilator Unit at Goldwater Memorial Hospital in New York City from 1980 to 1981, developed a noninvasive respiratory management program at the University of Poitiers, France from 1981 to 1983, and Medical Director of Kessler Institute for Rehabilitation Ventilator Unit in West Orange, N.J from 1993 to 1994.

Now the rehabilitation, professor of Neurosciences, the director of the New Jersey Medical School Muscular Dystrophy Association Clinic, and medical director of the Center for Ventilator Management Alternatives. He has over 400 peer reviewed scientific articles and book chapters and 7 medical textbooks on neuromuscular and pulmonary medicine and has lectured on these topics in over 60 countries.

If you would like to learn more about his work and techniques then please visit his website https://www.breathenvs.com

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more